课题基金 / 基金详情

Endoplasmic Reticulum Proteostasis to rescue Alpha1 AntiTrypsin Deficiency (acronym ERAAT) This is a proposal to the -Rare Joint Transnational Call for Proposals 2017 "Transnational Research Projects for Innovative Therapeutic Approaches for Rare Disease

Endoplasmic Reticulum Proteostasis to rescue Alpha1 AntiTrypsin Deficiency (acronym ERAAT) This is a proposal to the -Rare Joint Transnational Call for Proposals 2017 "Transnational Research Projects for Innovative Therapeutic Approaches for Rare Disease
内质网蛋白稳态拯救α1抗胰蛋白酶缺乏症(缩写ERAAT)这是一项针对2017年罕见疾病联合跨国提案征集“罕见疾病创新治疗方法跨国研究项目”的提案
批准号:
373006
负责人:
Thomas David Y
金额:
$16.35万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2017
资助国家:
加拿大
项目状态:
已结题
起止时间:
2017-06-01 至 2020-06-01

项目摘要

项目成果

Thomas David Y的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Alpha1-antitrypsin deficiency (ATD) is a rare disease caused by mutations in the alpha1-antitrypsin (A1AT) genes leading to improperly folded protein products unable to be secreted, and that in some instances aggregate in hepatocyte endoplasmic reticulum
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Canada Research Chair Tier 1
  • 批准号:
    315468
  • 项目类别:
  • 资助金额:
    $101.99万
  • 财政年份:
    2014
  • 负责人:
    Thomas David Y
  • 依托单位:
Biological variability of the response to protein trafficking correctors of cystic fibrosis
  • 批准号:
    237564
  • 项目类别:
    Operating Grants
  • 资助金额:
    $71.78万
  • 财政年份:
    2011
  • 负责人:
    Thomas David Y
  • 依托单位:
Therapeutic development of cystic fibrosis correctors
  • 批准号:
    182373
  • 项目类别:
    Operating Grants
  • 资助金额:
    $34.97万
  • 财政年份:
    2009
  • 负责人:
    Thomas David Y
  • 依托单位:
Cystic Fibrosis and ER Quality Control.
  • 批准号:
    181331
  • 项目类别:
    Operating Grants
  • 资助金额:
    $59.97万
  • 财政年份:
    2009
  • 负责人:
    Thomas David Y
  • 依托单位:
海外基金